Glucagon-like peptide-1 : New target for treating non-alcoholic fatty liver disease? / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
;
(12): 386-389, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-468519
ABSTRACT
Recent studies have demonstrated an association of glucagon-like peptide-1 (GLP-1) signaling defect with non-alcoholic fatty liver disease (NAFLD).Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes,resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism,and the suppression of oxidative stress in liver cells.Moreover,GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Endocrinology and Metabolism
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS